bs-4976R-Cy5 [Conjugated Primary Antibody]
Influenza A virus Nucleoprotein Polyclonal Antibody, Cy5 Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: Influenza A virus Nucleoprotein

Immunogen Range: 71-170/498


Clonality: Polyclonal

Isotype: IgG

Source: KLH conjugated synthetic peptide derived from Influenza A virus (strain A/Russia:St.Petersburg/8/2006 H1N1) Nucleoprotein

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

Encapsidates the negative strand viral RNA, protecting it from nucleases. The encapsidated genomic RNA is termed the ribonucleoprotein (RNP) and serves as template for transcription and replication. The RNP needs to be localized in the nucleus to start an infectious cycle, but is too large to diffuse through the nuclear pore complex. NP comprises at least 2 nuclear localization signals and is responsible of the active RNP import into the nucleus through the cellular importin alpha/beta pathway. Later in the infection, nucleus export of RNP are mediated through viral proteins NEP interacting with M1 which binds nucleoproteins. It is possible that the nucleoprotein binds directly exportin-1 (XPO1) and plays an active role in RNP nuclear export. M1 interaction with RNP seems to hide nucleoprotein's nuclear localization signals. Soon after a virion infects a new cell, M1 dissociates from the RNP under acidification of the virion driven by M2 protein. Dissociation of M1 from RNP unmask nucleoprotein's nuclear localization signals, targeting the RNP to the nucleus.

Conjugation: Cy5

Excitation/ Emission: 625,650nm/670nm

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:500-1000)

Predicted Molecular Weight: 56


Cross Reactive Species: Virus
(Influenza A virus)

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Chen, Hongjun, et al. "All-in-one bacmids: An efficient reverse genetics strategy for influenza A virus vaccines." Journal of Virology (2014): JVI-01468.Read more>>
  • Perez, Daniel R., and Hongjun Chen. "METHODS AND COMPOSITIONS FOR IN VIVO IMMUNE STIMULATION AND ANTIGEN PRODUCTION." U.S. Patent No. 20,160,022,807. 28 Jan. 2016.Read more>>
  • Qiuju Mouet al. EGCG induces -defensin 3 against influenza A virus H1N1 by the MAPK signaling pathway. Exp Ther Med. 2020 Oct;20(4):3017-3024.Read more>>